Patents Examined by Kahsay Habte
-
Patent number: 11779912Abstract: This invention relates generally to olefin metathesis catalyst compounds, to the preparation of such compounds, compositions comprising such compounds, methods of using such compounds, articles of manufacture comprising such compounds, and the use of such compounds in the metathesis of olefins and olefin compounds. The invention has utility in the fields of catalysts, organic synthesis, polymer chemistry, and industrial and fine chemicals industry.Type: GrantFiled: August 27, 2021Date of Patent: October 10, 2023Assignees: UMICORE AG & Co. KG, CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: Adam M. Johns, Jessica R. Herron, Richard L. Pederson, Bryan A. Fiamengo, Jennifer A. Beerman, Tzu-Pin Lin, Crystal K. Chu, Robert H. Grubbs
-
Patent number: 11780809Abstract: The N-(6-substitutedcarbazol-2-yl) acetamide compounds are antibacterial agents. The emergence of drug-resistant bacteria calls for constant development of new antibacterial agents with the aim of generating medicaments that are potent against drug sensitive and resistant bacteria and are well tolerated. The present compounds are not only new, but have very valuable antimicrobial properties. These compounds showed a broad spectrum of activity against gram-positive and gram-negative bacteria, as well tuberculosis mycobacteria. They also showed potent activity against drug-resistant bacteria, such as MRSA and VRSA. The molecular target of these compounds was identified as DNA Gyrase B. Based on their pharmacological profiles, the present compounds may find important clinical applications for severe infectious diseases and tuberculosis.Type: GrantFiled: March 9, 2023Date of Patent: October 10, 2023Assignee: KING FAISAL UNIVERSITYInventors: Christophe Tratrat, Michelyne Haroun
-
Patent number: 11773111Abstract: Novel dual 5-LO inhibitors of well validated electrophilic Michael acceptors and nitrogen-heterocycles are presented and designed to maintain specific structural features of currently known dual 5-LO inhibitors and to overcome their drawbacks. The Michael acceptor scaffold will act as a carrier and will provide a stable anchorage via covalent binding to cysteine/histidine residues within the catalytic cleft and/or the surface interface of the 5-LO; whereas, the nitrogen-heterocycles will ensure the access to the Fe(II) catalytic center. These combinations offer potential for more than one mode of iron chelation and 5-LO inhibition.Type: GrantFiled: November 29, 2022Date of Patent: October 3, 2023Assignee: KING FAISAL UNIVERSITYInventors: Saadeldin Elsayed Ibrahim Shabaan, Hany Mohamed Abd El-Lateef Ahmed
-
Patent number: 11773086Abstract: The present invention is directed to compounds, compositions, and methods for inhibiting drug-efflux pumps. The compounds, compositions, and methods can be used for enhancing the activity of therapeutic agents that are efflux pump substrates and for the treatment of drug-resistant diseases or disorders, such as microbial infections and cancers.Type: GrantFiled: August 31, 2021Date of Patent: October 3, 2023Assignees: TRUSTEES OF BOSTON UNIVERSITY, THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTOInventors: Lauren E. Brown, Kaddy Camara, Leah E. Cowen, John A. Porco, Jr., Kali Rae Iyer
-
Patent number: 11773052Abstract: Provided are a donor-acceptor type compound having a novel structure and its use.Type: GrantFiled: March 2, 2018Date of Patent: October 3, 2023Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Hideo Nagashima, Atsushi Tahara, Ikumi Kitahara, Yoichiro Kuninobu
-
Patent number: 11759462Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.Type: GrantFiled: March 15, 2021Date of Patent: September 19, 2023Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
-
Patent number: 11746100Abstract: The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I? and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.Type: GrantFiled: April 28, 2021Date of Patent: September 5, 2023Assignee: Global Blood Therapeutics, Inc.Inventors: Qing Xu, Carsten Alt, Zhe Li, Shahul Nilar, Peter Michael Rademacher, Calvin Wesley Yee
-
Patent number: 11746095Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.Type: GrantFiled: May 6, 2022Date of Patent: September 5, 2023Assignee: KINNATE BIOPHARMA INC.Inventors: Stephen W. Kaldor, Toufike Kanouni, Eric Murphy, Jason Cox, Robert Kania
-
Patent number: 11731964Abstract: The present invention generally relates to compounds as a new antibiotic to treat various infections, including infections caused by methicillin-resistant Staphylococcus aureus, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecalis and Clostridioides difficile. Pharmaceutical compositions and methods for treating those diseases are within the scope of this invention.Type: GrantFiled: March 29, 2019Date of Patent: August 22, 2023Assignee: Purdue Research FoundationInventors: Herman O. Sintim, Mohamed Seleem, Clement Opoku-Temeng, Haroon Taj Mohammad, George Naclerio
-
Patent number: 11730714Abstract: The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.Type: GrantFiled: December 14, 2018Date of Patent: August 22, 2023Assignee: NMD PHARMA A/SInventors: Thomas Holm Pedersen, Lars J. S. Knutsen, Nicholas M. Kelly, Martin Broch-Lips, Claus Elsborg Olesen, Marc Labelle, Ole Bækgaard Nielsen, Rajesh Kumar
-
Patent number: 11731939Abstract: The indole-based chalcone compounds are antibacterial agents. The emergence of drug-resistant bacteria calls for constant development of new antibacterial agents with the aim of generating medicaments that are potent against drug sensitive and resistant bacteria and are well tolerated. The present compounds are not only new, but have very valuable antimicrobial properties. These compounds showed a broad spectrum of activity against gram-positive and gram-negative bacteria, as well tuberculosis mycobacteria. They also showed potent activity against drug-resistant bacteria, such as MRSA and VRSA. The molecular target of these compounds was identified as DNA Gyrase B. Based on their pharmacological profiles, the present compounds may find important clinical applications for severe infectious diseases and tuberculosis.Type: GrantFiled: March 7, 2023Date of Patent: August 22, 2023Assignee: KING FAISAL UNIVERSITYInventors: Christophe Tratrat, Michelyne Haroun
-
Patent number: 11731948Abstract: Improved processes for producing high purity acesulfame potassium. In one embodiment, the process comprises the steps of contacting a solvent, e.g., dichloromethane, and a cyclizing agent, e.g., sulfur trioxide, to form a cyclizing agent composition and reacting an acetoacetamide salt with the cyclizing agent in the composition to form a cyclic sulfur trioxide adduct. The contact time is less than 60 minutes. The process also comprises forming from the cyclic sulfur trioxide adduct composition a finished acesulfame potassium composition comprising non-chlorinated, e.g., non-chlorinated, acesulfame potassium and less than 35 wppm 5-halo acesulfame potassium, preferably less than 5 wppm.Type: GrantFiled: March 19, 2021Date of Patent: August 22, 2023Assignee: Celanese International CorporationInventors: Christoph Mollenkopf, Peter Groer, Arvind Yadav
-
Patent number: 11724993Abstract: Compositions and processes for producing high purity acesulfame potassium are described. One process comprises the steps of forming a cyclic sulfur trioxide adduct; hydrolyzing the cyclic sulfur trioxide adduct to form an acesulfame-H composition comprising acesulfame-H; neutralizing the acesulfame-H in the acesulfame-H composition to form a crude acesulfame potassium composition comprising acesulfame potassium and less than 2800 wppm acetoacetamide-N-sulfonic acid, wherein the neutralizing step is conducted or maintained at a pH at or below 11.0; and treating the crude acesulfame potassium composition to form the finished acesulfame potassium composition comprising acesulfame potassium and less than 37 wppm acetoacetamide-N-sulfonic acid.Type: GrantFiled: March 19, 2021Date of Patent: August 15, 2023Assignee: Celanese International CorporationInventors: Christoph Mollenkopf, Peter Groer, Arvind Yadav
-
Patent number: 11724994Abstract: A process for producing acesulfame potassium, the process comprising the steps of providing a cyclizing agent composition comprising a cyclizing agent and a solvent and having an initial temperature, cooling the cyclizing agent composition to form a cooled cyclizing agent composition having a cooled temperature less than 35° C., reacting an acetoacetamide salt with the cyclizing agent in the cooled cyclizing agent composition to form a cyclic sulfur trioxide adduct composition comprising cyclic sulfur trioxide adduct; and, forming from the cyclic sulfur trioxide adduct in the cyclic sulfur trioxide adduct composition the finished acesulfame potassium composition comprising non-chlorinated acesulfame potassium and less than 39 wppm 5-chloro-acesulfame potassium. The cooled temperature is at least 2° C. less than the initial temperature.Type: GrantFiled: March 19, 2021Date of Patent: August 15, 2023Assignee: Celanese International CorporationInventors: Christoph Mollenkopf, Peter Groer, Arvind Yadav
-
Patent number: 11725011Abstract: The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.Type: GrantFiled: November 20, 2020Date of Patent: August 15, 2023Assignees: THE GENERAL HOSPITAL CORPORATION, DANA-FARBER CANCER INSTITUTE, INC., THE BROAD INSTITUTE, INC.Inventors: Nathanael S. Gray, Yanke Liang, Hwan Geun Choi, Thomas Sundberg, Alykhan Shamji, Ramnik Xavier, David E. Fisher, Nisma Mujahid
-
Patent number: 11725001Abstract: The present disclosure relates to a compound derivative containing a 6-7 bicyclic ring and use thereof. The compound according to the present invention can be effectively used in the prevention or treatment of diseases caused by PRMT5 by acting as a PRMT5 inhibitor.Type: GrantFiled: July 19, 2021Date of Patent: August 15, 2023Assignee: SK BIOPHARMACEUTICALS CO., LTD.Inventors: Yong Je Shin, Jin Hee Kim, Jun Lee, Sook Kyung Park, Ho Yeon Lee, Hyun Suk Choi, Se Hyuk Kim, Eun Ji Kang, Ho Youl Lee, Soo Yeon Jung
-
Patent number: 11718594Abstract: Compositions and processes for producing high purity acesulfame potassium are described. One process comprises the steps of providing a crude acesulfame potassium composition comprising acesulfame potassium and acetoacetamide, concentrating the crude acesulfame potassium composition to form a water stream and an intermediate acesulfame potassium composition comprising acesulfame potassium and less than 33 wppm acetoacetamide, and separating the intermediate acesulfame potassium composition to form the finished acesulfame potassium composition comprising acesulfame potassium and less than 33 wppm acetoacetamide. The concentrating step is conducted at a temperature below 90° C. and the separating step is conducted at a temperature at or below 35° C.Type: GrantFiled: March 19, 2021Date of Patent: August 8, 2023Assignee: Celanese International CorporationInventors: Christoph Mollenkopf, Peter Groer, Arvind Yadav
-
Patent number: 11718595Abstract: Compounds that inhibit p38? MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.Type: GrantFiled: June 16, 2021Date of Patent: August 8, 2023Assignee: University of Maryland, BaltimoreInventors: Paul S. Shapiro, Alexander D. Mackerell, Jr., Jeffrey D. Hasday, Steven Fletcher
-
Patent number: 11713327Abstract: The present invention relates to compounds of formula (I), ab (I), wherein R1 to R3 and L are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.Type: GrantFiled: June 11, 2019Date of Patent: August 1, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Fabian Dey, Buyu Kou, Haixia Liu, Hong Shen, Xiaoqing Wang, Weixing Zhang, Zhisen Zhang, Zhiwei Zhang, Wei Zhu
-
Patent number: 11708363Abstract: Disclosed herein relates to organic synthesis, and more particularly to a method for preparing a key intermediate for the synthesis of statins. The key intermediate is 2-[(4R,6S)-6-[(benzo[d]thiazol-2-ylthio)methyl]-2,2-disubstituted-1,3-dioxan-4-yl] acetate of formula (I): where R1 is a C1-C8 alkyl group, a C3-C8 cycloalkyl group, a monosubstituted or polysubstituted aryl group, or monosubstituted or polysubstituted aralkyl group; R2 is hydrogen, or monosubstituted or polysubstituted C1-C3 alkyl group, or halogen; and R3 and R4 are each independently a C1-C5 alkyl group, a C3-C7 cycloalkyl group, a C3-C7 cycloalkenyl group, a C1-C3 alkoxy group, a C6-C10 aryl group, or C7-C12 aralkyl group. In the method, a halomethyl compound and a thiol reagent are subjected to nucleophilic substitution in an organic solvent to synthesize a thioether, which then undergoes ketal exchange reaction with a carbonyl compound (V) in the presence of an organic acid to obtain a target product.Type: GrantFiled: September 28, 2021Date of Patent: July 25, 2023Assignee: Fudan UniversityInventors: Fener Chen, Dang Cheng, Minjie Liu, Zedu Huang, Yuan Tao, Jiaqi Wang